TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Lifestyle Intervention for Employees With Prediabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old~* overweight or obese~* prediabetes with elevated glucose value~Exclusion Criteria:~* recent cardiovascular event~* use of corticosteroids~* concurrent participation in a structured weight loss program~* pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lifestyle counseling (Type: EXPERIMENTAL): Diabetes Prevention Program lifestyle intervention
- Usual Care (Type: NO_INTERVENTION): Usual care from primary care physician

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial in Females for Female Pattern Hair Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* females, age 18 or older in general good health~* exhibits female pattern hair loss~* signs and dates an informed consent document~* agrees to use an adequate method of birth control; if of childbearing potential~* shows a negative urine pregnancy test at Screening Visit~* is willing to maintain the same hair style, hair color, and hair regimen throughout the study~* is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures~Exclusion Criteria:~* hypersensitivity to the (study product), or any ingredients of the (study product)~* known allergy to hair dye, or hair dye components~* clinically relevant history of hypotension~* untreated or uncontrolled hypertension~* pregnant, planning a pregnancy or nursing a child~* history of hair transplants~* currently use hair weaves or non-breathable wigs~* dermatologic disorders of the scalp that require chronic use of medication for control~* other types or history of hair loss~* enrolled in any other investigational medication (drug) study currently, or within the last 6 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Minoxidil Foam (Type: EXPERIMENTAL): 5% Minoxidil Topical Foam
- Vehicle Foam (Type: PLACEBO_COMPARATOR): Vehicle Topical Foam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Future Thinking Among Mothers to Reduce Harsh Parenting and Improve Child Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Be the mother from the Flint area of a child between the ages of 5-10 who can provide legal consent for that child to participate in this study~2. Self-report that the child lives with them for at least 50% of the time~3. Willing to participate in the study~4. Able to participate in written assessments and an intervention conducted in English~5. Have a working cell phone that can receive and send text messages and be willing to receive/send text messages as part of the study~6. Have a phone or device that's able to use video conferencing software~Exclusion Criteria:~1. Self-disclosed active suicidality/homicidality~2. Self-disclosed current bipolar disorder, schizophrenia, or psychosis~3. Current and ongoing involvement with child protective services

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Episodic Future Thinking (Type: EXPERIMENTAL): Mothers will receive episodic future thinking (EFT). Mothers will meet with a peer mother who will administer the EFT intervention, including generation of several specific future events reflecting positive interactions with their child. We will also teach each parent a behavioral parent training element called Special Play Time. Following this session, mothers will receive daily text messages over the course of two weeks including a reminder cue generated as part of the EFT and a prompt to remember these episodes in vivid detail.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female Subject Aged 18 To 26 Years~* With 1-4 Lifetime Sexual Partners~Exclusion Criteria:~* Male Subject

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she is using an acceptable method of birth control.~* 18 years or older~* Patient must have pain associated with cancer or cancer treatment.~* Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000 mg/day of oral morphine or 50 - 300 µg/hr of transdermal fentanyl (e.g. oxycodone 30 mg, methadone 20 mg, and hydromorphone 7.5 mg).~* Regularly experiences 1 - 4 breakthrough pain episodes per day that require additional opioids for pain control~* At least partial relief of breakthrough pain by use of opioid therapy~* Subject must be able to self-administer the study medication correctly.~* Subject must be willing and able to complete the electronic diary card with each pain episode.~* Signed consent must be obtained at screening prior to any procedures being performed.~Exclusion Criteria:~* Psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary~* Cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression~* Recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse~* Rapidly escalating pain that the investigator believes may require an increase in the dosage of background pain medication during the study~* Moderate (Grade 3) to severe (Grade 4) mucositis (Subjects with less than moderate mucositis are permitted and must be instructed to not apply the BEMA disc at a site of inflammation.)~* Strontium 89 therapy within the previous 6 months~* Any other therapy prior to the study that the investigator considers could alter pain or the response to pain medication.~* Use of an investigational drug within 4 weeks preceding this study~* History of hypersensitivity or intolerance to fentanyl~* Regularly more than 4 episodes per day~* Eastern Cooperative Oncology Group (ECOG) performance status of 4 or 5~* Subject is pregnant, actively trying to become pregnant, breast feeding or not using adequate contraceptive measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- BEMA™ Fentanyl (Type: EXPERIMENTAL): BioErodible MucoAdhesive (BEMA) Fentanyl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 12 years of age or older, of either sex and of any race.~* Must have at least a 2-year documented history of SAR which exacerbates during the study season.~* Must have a positive skin-prick test response to an appropriate seasonal allergen at Screening (Visit 1). Immunoglobulin E (IgE)-mediated hypersensitivity to an appropriate seasonal allergen (ie, prevailing trees and/or grasses) must be documented by a positive response to the skin prick test with wheal diameter at least 3 mm larger than diluent control after 20 minutes.~* Must be clinically symptomatic at the Screening Visit.~* Must be clinically symptomatic at the Baseline Visit.~* Must be in general good health as confirmed by routine clinical and laboratory testing and electrocardiogram (ECG) results. Clinical laboratory test (complete blood count \[CBC\], blood chemistries, and urinalysis) must be within normal limits or clinically acceptable to the investigator and the sponsor.~* Must be free of any clinically significant disease, other than SAR, that would interfere with the study evaluations.~Exclusion Criteria:~* A history of anaphylaxis and/or other severe local reaction(s) to skin testing.~* A subject with asthma who requires chronic use of inhaled or systemic corticosteroids.~* Current or history of frequent, clinically significant sinusitis or chronic purulent postnasal drip.~* A subject with rhinitis medicamentosa.~* A history of allergies to more than two classes of medications or who are allergic to or cannot tolerate nasal sprays.~* A subject who has had an upper respiratory tract or sinus infection that required antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or who has had a viral upper respiratory infection within 7 days before the Screening Visit.~* A subject who has nasal structural abnormalities, including large nasal polyps and marked septal deviations, which significantly interfere with nasal air flow.~* A subject who, in the opinion of the investigator, is dependent on nasal, oral, or ocular decongestants, nasal topical antihistamines, or nasal steroids.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MFNS 200 mcg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must meet all the following inclusion criteria to be eligible for inclusion in the study.~  1. Diagnosed with Atrial fibrillation (AF) anytime in the baseline period or on the index date, also have definitive diagnosis of AF anytime in the baseline period, on the index date, or post-index period.~ 2. Prescribed apixaban or warfarin on or after the day of AF diagnosis. The first observed prescription will be used to identify the patient's index date and treatment cohort~ 3. No use of the any Oral anticoagulants (OAC)s during the baseline period (the 180 days before the index date)~ 4. Age of 18 years or older on the index date.~ 5. Index date is at age 80 or older~Exclusion Criteria:~* Patients meeting any of the following criteria will not be included in the study:~  1. Having a diagnosis of valvular atrial fibrillation, post-operative atrial fibrillation, rheumatic atrial fibrillation or mechanical-valvular atrial fibrillation during the baseline and post-index period~ 2. Having a cardiac surgery procedure record during the baseline period~ 3. Having a joint replacement procedure record during the baseline period~ 4. Having a procedure of prosthetic heart valve during the baseline period~ 5. Having a diagnosis of venous thromboembolism during the baseline period~ 6. Female patients with pregnancy during the follow-up period~ 7. Patients prescribed off-label doses of OACs (per Japanese package insert of each OAC) or patients treated with OAC but in off-label or contraindicated manners.

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Warfarin cohort (Reference) (Type: None): Patients with NVAF treated with warfarin
- Apixaban cohort (Type: None): Patients with NVAF treated with apixaban

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged over 65 hospitalized for upper or lower GI bleeding with positve outcome during hospitalization without surgery, and with persistent anaemia (Hb \<11g/dL),~2. Signed informed consent,~3. Patients with National Health Insurance,~Exclusion Criteria:~1. Uncontrolled haemorrhage defined by any new externalizing and / or a decrease of haemoglobin and haematocrit levels,~2. GI bleeding related to portal hypertension or malignancy,~3. The absence of anaemia,~4. Cancer evolution,~5. Patient under guardianship, curatorship or unable to supply consent,~6. Iron overload,~7. History of asthma~8. History of eczema~9. Hypersensitivity to any component~10. Decompensated liver cirrhosis~11. Infection during treatment or uncontrolled infection 12 Rheumatoid arthritis~13. Acute renal failure

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferinject 1000 mg (Type: EXPERIMENTAL): Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous administration of 250 ml of sodium chlorure 0.9 %

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female (age 35-80)~* Previously diagnosed with MetS and/or T2DM as measured by possessing at least two of the following physiological measures: type 2 diabetes, BMI \> 30, HgA1c \> 5.7%, waist/height ratio \> .6, fasting glucose \> 125 mg/dL~* Subjective Memory Complaints (SCM) - Subjects score \> 3 'yes' answers on the Subjective Memory Complaints Questionnaire~* Previously diagnosed with Mild Cognitive Impairment (MCI)~Exclusion Criteria:~* Previously diagnosed with Alzheimer's disease (AD), dementia or Parkinson's disease

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week.
- Control group (Type: ACTIVE_COMPARATOR): Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Males and Females at least 18 years of age~* Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery~* ECOG Performance status of 0 or 1~* Available tumor sample for testing~* Acceptable blood work~Exclusion Criteria:~* Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas~* Prior chemotherapy for pleural mesothelioma~* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody~* History of other malignancy unless the subject has been disease-free for at least 3 years~* Active, untreated central nervous system (CNS) metastasis~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab and Ipilimumab (Type: EXPERIMENTAL): Specified dose on specified days
- Pemetrexed and Cisplatin (or Carboplatin) (Type: ACTIVE_COMPARATOR): Specified dose on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with a diagnosis of HES, CEL and CIH, who are either previously untreated or have been treated with corticosteroids, cytotoxic drugs, and IFN.~* age \> 15 years.~* signature of a written informed consent(by parents/tutors for patients aged \< 18 years).~Exclusion Criteria:~* patients with a diagnosis of secondary hypereosinophilia~* age \< 15 years

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: EXPERIMENTAL): Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BG00012 in MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Must be 18 to 55 years old, inclusive, at the time of informed consent.~2. Must have a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4 (McDonald et al, 2001; Appendix 2).~3. Must have a baseline EDSS between 0.0 and 5.0, inclusive.~4. Must have experienced at least one relapse within the 12 months prior to randomization, with a prior cranial MRI demonstrating lesion(s) consistent with MS OR show evidence of Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks.~5. Male and female subjects must be willing to take appropriate measures to prevent pregnancy.~Exclusion Criteria:~1. Primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996 \[Appendix 3\]).~2. History of malignancy.~3. History of severe allergic or anaphylactic reactions or known drug hypersensitivity.~4. History of abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic (other than MS), and/or other major disease.~5. History of human immunodeficiency virus (HIV).~6. History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization.~7. An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization.~8. Body weight \>100 kg.~9. Positive for hepatitis C antibody and/or positive for hepatitis B surface antigen (HBsAg) at screening.~10. Any of the following abnormal blood tests at screening.~11. Any previous treatment with FUMADERM®, FAG-201, or BG00012.~12. A medication history that precludes entry into the study.~13. Female subjects who are currently pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete